Medication info
DS Tablet 80 mg (Valsartan)

DS Tablet 80 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›80mg / 1 tablet
Manufacturer / importer
Poonglim Pharmaceutical Co., Ltd.
Appearance
Pale pink, biconvex round film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201308441 · Approved 2013.07.29 · Insurance code 649001100

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When a diuretic is administered concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
Safety and efficacy have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Poonglim Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular failure
  • left ventricular systolic dysfunction
View approved original text

This medication is effective for patients with essential hypertension and heart failure who cannot use ACE inhibitors. It is also used to reduce the risk of death in clinically stable patients with left ventricular failure or impaired left ventricular function following myocardial infarction. In other words, it helps in controlling blood pressure and preventing heart-related complications. This efficacy contributes to improving the cardiovascular health of patients.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg per day or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg per day. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily, and do not exceed 80 mg per day. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily, and the dose may be increased to 80 mg or 160 mg per dose. When a diuretic is administered concomitantly, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks to 40 mg, 80 mg, and 160 mg per dose twice daily, taking the patient's tolerability into account. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or greater; however, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

Safety and efficacy have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication or its ingredients, pregnant or lactating women, and patients with severe liver or kidney disease should not take this medication. Elderly patients, patients with hyperkalemia, liver disease, or heart disease require special caution while taking this medication, and it is advisable to start with a low dose and closely monitor the condition. This medication lowers blood pressure and may cause a rapid drop in blood pressure upon initial administration, leading to dizziness or fainting; hence caution is advised, especially for patients taking diuretics or those who are volume depleted. Regular blood tests to monitor kidney function and serum potassium levels during the medication period are important. Drug interactions may occur when taken with other antihypertensive medications, certain diuretics, or potassium supplements, so consultation with a physician or pharmacist before use is recommended. Dizziness or drowsiness may occur; caution is required when driving or operating machinery. If symptoms of angioedema, such as swelling of the face, lips, or tongue occur, discontinue use immediately and visit a medical institution. Severe hypotension or loss of consciousness can occur in cases of overdose, so immediate medical assistance is required. The safety and efficacy in children and adolescents under 18 years of age have not been adequately established, and its use should be avoided. This medication should be stored out of reach of children, and transferring to another container may compromise quality, so caution is required.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 56 more
  • stomach pain
  • nausea
  • pharyngitis
  • joint pain
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • arrhythmia
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • loss of appetite
  • malaise
  • vascular edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • hepatitis
  • syncope
  • epistaxis
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • decreased red blood cell volume
  • decreased hemoglobin
  • neutropenia
  • increased serum creatinine
  • increased total bilirubin
  • increased BUN
  • dyspepsia
  • anemia
  • tinnitus
  • tension increase
  • decreased exercise capacity
  • confusion
  • chest pain
  • rash
  • myalgia
  • edema
  • asthenia
  • insomnia
  • decreased libido
  • hypotension
  • unsteadiness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture, and it is recommended to keep it in a cool place below 30°C. Therefore, it is safe to avoid direct sunlight, high temperatures, and humid places.

Appearance and packaging

Appearance

Pale pink, biconvex round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.